Trials / Completed
CompletedNCT01714661
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 753 (actual)
- Sponsor
- FORUM Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EVP-6124 | Arms 1, 2 |
| DRUG | Placebo | Arm 3 |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2012-10-26
- Last updated
- 2016-05-03
Locations
94 sites across 13 countries: United States, Argentina, Australia, Brazil, Canada, Germany, Mexico, Poland, Russia, Serbia, Singapore, Spain, Ukraine
Source: ClinicalTrials.gov record NCT01714661. Inclusion in this directory is not an endorsement.